Table 1.
Baseline characteristics of 837 PLHIV-PWUD, stratified by VL suppression (<200 copies/mL), Vancouver, Canada (1996–2017).
| Characteristic | Total, No. (%) (n = 837) | VL suppression, No. (%) |
|
|---|---|---|---|
| Yes (n = 408) | No (n = 429) | ||
|
| |||
| Individual-level | |||
|
| |||
| Age in years, Median (Q1–Q3) | 39 (32.8–45.1) | 42.5 (35.5–47.9) | 36.6 (31.1–42.3) |
| Male | 558 (66.7) | 276 (49.5) | 282 (50.5) |
| White | 454 (54.2) | 221 (48.7) | 233 (51.3) |
| History of injection drug use | 779 (93.1) | 382 (49) | 397 (51) |
|
| |||
| ART-related characteristics | |||
|
| |||
| ART category | |||
| PI (boosted) | 307 (36.7) | 194 (63.2) | 113 (36.8) |
| PI (un-boosted) | 113 (13.5) | 22 (19.5) | 91 (80.5) |
| NNRTI | 274 (32.7) | 165 (60.2) | 109 (39.8) |
| INSTI | 21 (2.5) | 17 (81) | 4 (19) |
| Other | 122 (14.6) | 10 (8.2) | 112 (91.8) |
| ART adherence | |||
| ≥95% | 304 (36.3) | 238 (78.3) | 66 (21.7) |
| 90 to <95% | 36 (4.3) | 25 (69.4) | 11 (30.6) |
| 85 to <90% | 49 (5.9) | 30 (61.2) | 19 (38.8) |
| 80 to <85% | 32 (3.8) | 18 (56.2) | 14 (43.8) |
| 50 to <80% | 138 (16.5) | 55 (39.9) | 83 (60.1) |
| <50% | 278 (33.2) | 42 (15.1) | 236 (84.9) |
| Calendar-year of observation | |||
| 1996–1999 | 193 (23.1) | 13 (6.7) | 180 (93.3) |
| 2000–2005 | 204 (24.4) | 93 (45.6) | 111 (54.4) |
| 2006–2009 | 194 (23.2) | 129 (66.5) | 65 (33.5) |
| 2010–2015 | 228 (27.2) | 158 (69.3) | 70 (30.7) |
| 2016–2017 | 18 (2.2) | 15 (83.3) | 3 (16.7) |
| Physician experience, Median (Q1–Q3) | 71 (26–180) | 89 (40–231.5) | 71 (19–135) |
PLHIV, people living with HIV; PWUD, people who use drugs; VL, viral load; Q1–Q3, quartile 1–quartile 3; ART, antiretroviral therapy; PI, protease inhibitors; NNRTI, nonnucleoside reverse transcriptase inhibitors; INSTI, integrase strand transfer inhibitor. Percentages (%) in the VL suppression (Yes/No) columns were calculated as row percentages (e.g., 276/558 = 49.5%)